Article
Cell Biology
Shaohua Huang, Liping Ma, Biyang Lan, Ning Liu, Wenwei Nong, Zhihu Huang
Summary: Through bioinformatic analyses, key dysregulated genes associated with the development of gastric cancer were identified, showing potential prognostic value. High expression of LRFN4 and LOC100506388 was linked to a higher risk of gastric cancer, while tumor infiltration levels were associated with overall survival in patients.
Article
Immunology
Jing Yang, Hui Wei, Mengxiao Liu, Taobi Huang, Xidong Fang, Xiangqing Ren, Hao Yuan, Ya Zheng, Yuping Wang, Yongning Zhou
Summary: This study found that high expression of HAMP is associated with poor prognosis in gastric cancer, and HAMP affects the survival rate of patients with gastric cancer through immune cell infiltration.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Genetics & Heredity
Jiao Li, Shan Tian, Yingyun Guo, Weiguo Dong
Summary: AMAP1 mRNA and protein levels were found to be upregulated in gastric cancer specimens compared to normal tissues. High AMAP1 mRNA abundance was associated with poor overall survival and reduced progression-free survival in patients with gastric cancer. AMAP1 was negatively correlated with miR-192-3p and acted as a novel oncogene in gastric cancer, serving as a potential diagnostic and prognostic marker.
FRONTIERS IN GENETICS
(2021)
Article
Anatomy & Morphology
Deqin Li, Tiantian Qi, Jian Chen
Summary: This study found that SAMD4A is highly expressed in gastric cancer and is associated with poor prognosis in patients. SAMD4A promotes the proliferation, invasion, and migration abilities of gastric adenocarcinoma cells. This indicates that SAMD4A plays an important role in the occurrence and development of gastric cancer and could be an effective indicator for the diagnosis and prognosis evaluation of gastric cancer.
Article
Oncology
Nil Grunberg, Meirav Pevsner-Fischer, Tal Goshen-Lago, Judith Diment, Yaniv Stein, Hagar Lavon, Shimrit Mayer, Oshrat Levi-Galibov, Gil Friedman, Yifat Ofir-Birin, Li-Jyun Syu, Cristina Migliore, Eyal Shimoni, Salomon M. Stemmer, Baruch Brenner, Andrzej A. Dlugosz, David Lyden, Neta Regev-Rudzki, Irit Ben-Aharon, Ruth Scherz-Shouval
Summary: This study used RNA sequencing of CAFs from gastric cancer patients to identify a stromal gene signature associated with aggressive gastric cancer, with HSF1 playing a key regulatory role in this signature. HSF1 upregulates inhibin subunit beta A and thrombospondin 2, which are secreted in CAF-derived extracellular vesicles to promote cancer progression.
Article
Oncology
Yunfei Wang, Jiadong Pan, Fangmei An, Ke Chen, Jiawei Chen, He Nie, Yanping Zhu, Zhengtao Qian, Qiang Zhan
Summary: In this study, the expression, prognostic value, and immune-correlations of guanylate-binding protein 2 (GBP2) in gastric cancer were investigated. The results showed that GBP2 was highly expressed in tumor tissues and associated with poor prognosis. It was also found that GBP2 was related to the immune-hot phenotype and had positive correlations with immuno-modulators, tumor-infiltrating immune cells, immunotherapy biomarkers, and immunotherapeutic response. Additionally, GBP2 was expected to be an indicator of high immunogenicity in most cancer types. Importantly, GBP2 could predict the immunotherapeutic responses in at least four different cancer types.
Article
Oncology
Jun-Yan Liu, Jing Yao, Jia-Jia Liu, Tao He, Fang-Jie Wang, Tian-Yu Xie, Jian-Xin Cui, Xiao-Dong Yang
Summary: In this study, a novel survival-related ferroptosis-related lncRNA (FRlncRNA), LASTR, was identified in gastric cancer (GC). High expression of LASTR was associated with shorter overall survival and progression-free survival of GC patients. Knocking down LASTR had a significant effect on reducing the proliferation of GC cells. Additionally, the expression of LASTR was negatively associated with certain immune cells. These findings suggest that LASTR may serve as a novel prognostic biomarker for predicting response to cancer immunotherapy and therapeutic target for GC patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, Research & Experimental
Jing Liu, Xingwu Zhu, Meinan Yan, Hui Li
Summary: In this study, a predictive model named circPanel was established based on two highly expressed circRNAs (hsa_circ_0005092 and hsa_circ_0002647) in gastric cancer patients with good prognoses, showing potential as a prognostic biomarker with greater accuracy than single circRNAs and traditional tumor markers. Functional analysis and network prediction were also performed for these circRNAs.
JOURNAL OF TRANSLATIONAL MEDICINE
(2021)
Review
Biochemistry & Molecular Biology
Woong Kim, Seok-Jun Kim
Summary: HSF1, a highly expressed gene in various cancers, is correlated with the prognosis of gastric cancer patients, serving as a potential biomarker.
Article
Oncology
Secil Demirkol Canli, Meral Uner, Baris Kucukkaraduman, Diren Arda Karaoglu, Aynur Isik, Nesrin Turhan, Aytekin Akyol, Ismail Gomceli, Ali Osmay Gure
Summary: By analyzing the transcriptomic data from primary gastric tumors, a novel list of 20 prognostic genes was identified, and gastric tumors were classified into two subgroups based on stromal gene expression (Stromal-UP and Stromal-DOWN). The Stromal-UP subgroup showed a more mesenchymal profile and a poor prognosis. It was also found that a higher stromal content in FFPE tissues was associated with shorter overall survival.
Article
Biotechnology & Applied Microbiology
Diqun Chen, Rouxin Zhang, Aosi Xie, Jinpeng Yuan, Jinhai Zhang, Yongjian Huang, Hongxia Zhang, Feiran Zhang
Summary: Gastric cancer is among the most common and deadly cancers globally. This study reveals that NUDT10 expression is significantly reduced in GC tissues compared to normal tissues, and high expression is associated with worse prognosis in terms of tumor malignancy and survival outcomes. NUDT10 shows potential as an independent biomarker for GC prognosis.
Article
Multidisciplinary Sciences
Wenfang Zhao, Jiahui Lin, Sha Cheng, Huan Li, Yufeng Shu, Canxia Xu
Summary: This study found that COMMD10 was highly expressed in gastric adenocarcinoma (STAD) and was associated with poor prognosis. Additionally, COMMD10 was related to m6A modification and immune infiltration in STAD.
Article
Immunology
Jiannan Xu, Songyao Chen, Jianming Liang, Tengfei Hao, Huabin Wang, Guangyao Liu, Xinghan Jin, Huan Li, Junchang Zhang, Changhua Zhang, Yulong He
Summary: The SLFN gene family is highly expressed in gastric cancer patients and is associated with lymph node metastasis, tumor stage, tumor grade, and poor prognosis. The genetic alterations of the SLFN family in gastric cancer are frequent, including mutations and amplifications. The SLFN family interacts with multiple genes and proteins and may be involved in immune response and immune cell infiltration in gastric cancer. Additionally, the SLFN family may regulate T cell activation and contribute to immune evasion in gastric cancer.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Zequn Li, Yuqi Sun, Jianfei Xu, Hao Yang, Xiaodong Liu, Yulong Tian, Shougen Cao, Yanbing Zhou
Summary: ITGB6 expression is associated with poor prognosis in gastric cancer patients, with high expression levels indicating worse outcomes. Serum ITGB6 expression is correlated with tumor tissue expression, and combining it with other markers like CEA can effectively predict the risk and prognosis of gastric cancer patients. The study also found that changes in serum ITGB6 levels post-surgery could indicate tumor recurrence or progression, highlighting its potential as a valuable biomarker for risk stratification and surveillance in gastric cancer patients.
FRONTIERS IN ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Chen Zhang, Tao Liu, Jian Wang, JianTao Zhang
Summary: This study investigated the transcriptomic signature of immune genes in gastric cancer and identified an immune-related prognostic biomarker that can predict patient prognosis and response to immunotherapy.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Yongcan Xu, Qiuyuan Xia, Qiu Rao, Shanshan Shi, Qunli Shi, Henghui Ma, Zhenfeng Lu, Hui Chen, Xiaojun Zhou
Article
Oncology
Xue Xu, Yongcan Xu, Chuanqin Shi, Baoyu Wang, Xiang Yu, Yanfen Zou, Tao Hu
Article
Oncology
Yan Chen, Xiang Yu, Yongcan Xu, Hua Shen
Article
Oncology
Wei Lu, Yongcan Xu, Jiewei Xu, Zhong Wang, Guochao Ye
Article
Biotechnology & Applied Microbiology
Hao Jiang, Xuefei Shi, Guochao Ye, Yongcan Xu, Jiewei Xu, Jun Lu, Wei Lu
ONCOTARGETS AND THERAPY
(2019)
Review
Medicine, Research & Experimental
Xuefei Shi, Bin Wang, Xueren Feng, Yongcan Xu, Kaihua Lu, Ming Sun
MOLECULAR THERAPY-NUCLEIC ACIDS
(2020)